scholarly journals European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure

2020 ◽  
Vol 22 (2) ◽  
pp. 196-213 ◽  
Author(s):  
Petar M. Seferović ◽  
Andrew J.S. Coats ◽  
Piotr Ponikowski ◽  
Gerasimos Filippatos ◽  
Martin Huelsmann ◽  
...  
Keyword(s):  
Heart Failure ◽  
European Society ◽  
Position Paper ◽  
Glucose Lowering ◽  
Patients With Heart Failure ◽  
European Society Of Cardiology

scholarly journals Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure

2019 ◽  
Vol 21 (11) ◽  
pp. 1299-1305 ◽  
Author(s):  
Cristiana Vitale ◽  
Ewa Jankowska ◽  
Loreena Hill ◽  
Massimo Piepoli ◽  
Wolfram Doehner ◽  
...  
Keyword(s):  
Heart Failure ◽  
European Society ◽  
Position Paper ◽  
Patients With Heart Failure ◽  
European Society Of Cardiology

scholarly journals Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

2020 ◽  
Vol 41 (22) ◽  
pp. 2109-2117 ◽  
Author(s):  
Stefan D Anker ◽  
Javed Butler ◽  
Muhammad Shahzeb Khan ◽  
William T Abraham ◽  
Johann Bauersachs ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
European Society ◽  
Clinical Care ◽  
Position Paper ◽  
Adverse Outcomes ◽  
Web Based ◽  
Effective Care ◽  
America South ◽  
European Society Of Cardiology

Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has important implications for the safety of participants in clinical trials and the research staff caring for them and, consequently, for the trials themselves. Patients with heart failure may be at greater risk of infection with COVID-19 and the consequences might also be more serious, but they are also at risk of adverse outcomes if their clinical care is compromised. As physicians and clinical trialists, it is our responsibility to ensure safe and effective care is delivered to trial participants without affecting the integrity of the trial. The social contract with our patients demands no less. Many regulatory authorities from different world regions have issued guidance statements regarding the conduct of clinical trials during this COVID-19 crisis. However, international trials may benefit from expert guidance from a global panel of experts to supplement local advice and regulations, thereby enhancing the safety of participants and the integrity of the trial. Accordingly, the Heart Failure Association of the European Society of Cardiology on 21 and 22 March 2020 conducted web-based meetings with expert clinical trialists in Europe, North America, South America, Australia, and Asia. The main objectives of this Expert Position Paper are to highlight the challenges that this pandemic poses for the conduct of clinical trials in heart failure and to offer advice on how they might be overcome, with some practical examples. While this panel of experts are focused on heart failure clinical trials, these discussions and recommendations may apply to clinical trials in other therapeutic areas.

scholarly journals Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology

2019 ◽  
Vol 21 (5) ◽  
pp. 553-576 ◽  
Author(s):  
Petar M. Seferović ◽  
Marija Polovina ◽  
Johann Bauersachs ◽  
Michael Arad ◽  
Tuvia Ben Gal ◽  
...  
Keyword(s):  
Heart Failure ◽  
European Society ◽  
Position Paper ◽  
European Society Of Cardiology
Sign in / Sign up

Export Citation Format

Share Document